127020-07-9

Basic information

• Product Name: 1H-IMIDAZOLE-2-CARBOXALDEHYDE OXIME
• Synonyms: 1H-IMIDAZOLE-2-CARBOXALDEHYDE OXIME;1H-Imidazol-2-carboxaldehyde oxime
• CAS NO: 127020-07-9
• Molecular Formula: C4H5N3O
• Molecular Weight: 111.1
• Mol File: 127020-07-9.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-IMIDAZOLE-2-CARBOXALDEHYDE OXIME(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-IMIDAZOLE-2-CARBOXALDEHYDE OXIME(127020-07-9)
• EPA Substance Registry System: 1H-IMIDAZOLE-2-CARBOXALDEHYDE OXIME(127020-07-9)

Safety Data

• Hazardous Substances Data: 127020-07-9(Hazardous Substances Data)

Usage

Molecular weight

114.11 g/mol

Common uses

Reagent in organic synthesis, particularly in the preparation of heterocyclic compounds

Applications

Versatile building block in the pharmaceutical industry, used in the synthesis of various drugs and bioactive molecules

Uses in medicinal chemistry

Chelating agent, ligand in metal catalysis, precursor in the synthesis of azole-based drugs

Unique properties

Valuable tool in chemical and pharmaceutical research due to its molecular structure and reactivity.

Upstream product

• 10111-08-7 2-imidazolecarbaldehyde 

Downstream Products

• 22600-77-7 (1H-imidazol-2-yl)methanamine dihydrochloride 

Relevant articles and documents

Synthesis of oxime-based CO-releasing molecules, CORMs and their immobilization on maghemite nanoparticles for magnetic-field induced CO release

Oxime-based CO-releasing molecules (oximeCORMs) were immobilized with a catechol-modified backbone on maghemite iron oxide nanoparticles (IONPs) to give oximeCORM@IONP. The CO release from the free and immobilized oximeCORMs was measured using the standard myoglobin assay. The oximeCORM-nanoparticles were coated with dextran for improved water solubility and confined into an alginate shell for protection and separation from the surrounding myoglobin assay to allow for CO release studies by UV/Vis absorption without interference from highly-absorptive oximeCORM@IONP. Half-lifes of the oxime-based polymer-confined alginate@dextran@oximeCORM@IONPs were estimated at 20 °C to 814 ± 23 min, at 37 °C to 346 ± 83 min and at 50 °C to 73 ± 1 min. The alginate@dextran@oximeCORM@IONP composite showed a further decrease of the half-life of CO release to 153 ± 27 min at 37 °C through local magnetic heating of the susceptible iron oxide nanoparticles with application of an external alternating magnetic field (31.7 kA m-1, 247 kHz, 39.9 mTesla). The activation energy for the CO release from molecular dicarbonylchlorido(imidazole-2-carbaldehydeoxime)(alkoxycarbonyl)ruthenium(ii) complexes is determined to be ～100 kJ mol-1 for five different imidazole-oxime derivatives.

Synthesis and characterization of bisimidazolylfuroxan derivatives

-

Synthesis and ocular effects of imidazole nitrolic acids

Novel 1-R-imidazole-2-nitrolic acids and 1-R-imidazole-5-nitrolic acids (R: H, Me, Bn) were synthesized from oximes by treatment with a mixture of fuming nitric acid and acetic acid. The effects of these potential nitric oxide-donating compounds were test